ARTICLE | Deals
Vir speeding COVID-19 mAbs into Phase II with $250M GSK investment
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
April 6, 2020 2:52 PM UTC
Updated on Apr 17, 2020 at 12:24 PM UTC
A $250 million investment by GlaxoSmithKline will put the clinical trial expertise and regulatory acumen of one of the leading anti-infective drug companies behind Vir’s effort to bring an antibody therapy to fight against COVID-19, Vir CEO George Scangos told BioCentury Monday.
Vir Biotechnology Inc. (NASDAQ:VIR) expects to start a Phase II trial within three to five months of two versions of an antibody product, VIR-7831 and VIR-7832, which target the spike protein of SARS-CoV-2, and are administered via intramuscular injection...